Targeted Transcranial Magnetic Stimulation to Improve Hippocampal-dependent Declarative Memory Abilities
University of Nebraska · NCT03574207
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 19+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 80
- US sites recruiting
- 1
- Study start
- January 1, 2019
- Record last updated
- March 25, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This is a pilot study of non-invasive transcranial magnetic stimulation (TMS) to improve memory in healthy adults. It will also examine treating memory deficits in older adults with amnestic mild cognitive impairment (aMCI), a condition that frequently precedes Alzheimer's disease (AD). The study will test whether a form of non-invasive brain stimulation repetitive transcranial magnetic stimulation (rTMS) can improve memory abilities in healthy young adults, healthy older adults, and older adults with aMCI by retuning memory-related brain networks. This study is a key first step which will support the long-term goal of treating memory deficits in neurological patients. It is expected that rTMS will improve memory abilities in all participants, and that the improvements in memory will be attributable to changes in the connectivity of memory-related brain networks.
Being studied: Transcranial magnetic stimulation
Conditions: Mild Cognitive Impairment; Memory Loss
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
The investigators anticipate enrolling 48 subjects total:
- 16 healthy young adults (age 19-35)
- 16 healthy older adults (demographically matched to aMCI group for age, sex, and educational attainment)
- 16 older adults diagnosed with amnestic mild cognitive impairment (aMCI)
Inclusion Criteria
- Adults 19 years of age and older
- Healthy adults without history of psychiatric or neurological disease OR previous diagnosis of amnestic MCI
- Must be able to provide informed consent
- Must have the ability to comply with basic instructions and have the ability to sit comfortably still for TMS, neuroimaging, and other study procedures.
- Right-handed based on self-report (pre-screening) and evaluation with a standard test.
Exclusion Criteria
- Individuals who have ferrous metal implanted in their body (other than in their teeth) or any other non-removable medical and/or metallic implant
- Individuals who have increased intracranial pressure
- Individuals who have any major medical illness (e.g., cancer, HIV+, hepatitis, heart disease)
- Individuals who have confounding/dual diagnoses (e.g., comorbid mental illness and substance use disorder)
- Individuals with current diagnoses of alcohol or substance abuse/dependence
- Individuals with epilepsy, any history of seizures, or using medication that lowers seizure threshold
- Individuals with any neurological disorder other than aMCI (e.g., stroke, traumatic brain injury)
- Pregnant females --- as determined by urine pregnancy test --- will be excluded from this study due to uncertainty of the effects of MRI and TMS on the fetus
- Not right-handed based on self-report (pre-screening) or evaluation with a standard test
- Not a native English speaker.
Recruiting US locations
University of Nebraska Medical Center
Omaha, NE 68198
Site contact: David E Warren, PhD · 402-559-5805 · david.warren@unmc.edu
Study contacts (from the official record)
- Anna Wilhelm, MA · 402-559-5805 · wnl@unmc.edu
Similar studies in Nebraska
All neurology studies in Nebraska →- RecruitingPhase 3
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated
- Location
- Norfolk, NE + 57 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
Rapport Therapeutics Inc.
- Location
- Omaha, NE + 12 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
Pfizer
- Location
- Grand Island, NE + 28 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine
Pfizer
- Location
- Papillion, NE + 15 other US sites
- Eligibility basics
- Ages 18+